{
  "metadata": {
    "case_id": 92,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T19:31:45.762272",
    "total_alignments": 2,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/92_NCT02981602.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/92_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.55,
          0.6,
          0.2,
          0.68,
          0.05
        ],
        [
          0.2,
          0.12,
          0.52,
          0.2,
          0.72
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 3,
          "score": 0.68,
          "status": "matched",
          "ref_item": {
            "label": "IONIS-HBVRx",
            "type": "EXPERIMENTAL",
            "description": "Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection",
            "interventionNames": [
              "Drug: IONIS-HBVRx"
            ]
          },
          "pred_item": {
            "label": "On-NA: Bepirovirsen 300 mg",
            "type": "EXPERIMENTAL",
            "description": "Patients with chronic hepatitis B already receiving stable nucleos(t)ide analog (NA) therapy (tenofovir disoproxil fumarate or entecavir for ≥12 months) received bepirovirsen 300 mg via subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8, 11) and once weekly during weeks 3 and 4 (days 15, 22). Patients continued their stable NA therapy throughout the study until end of study (day 211).",
            "interventionNames": [
              "DRUG: Bepirovirsen 300 mg",
              "DRUG: Nucleos(t)ide analog (tenofovir disoproxil fumarate or entecavir)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 4,
          "score": 0.72,
          "status": "matched",
          "ref_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator",
            "interventionNames": [
              "Drug: Placebo"
            ]
          },
          "pred_item": {
            "label": "On-NA: Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients with chronic hepatitis B already receiving stable nucleos(t)ide analog (NA) therapy (tenofovir disoproxil fumarate or entecavir for ≥12 months) received placebo via subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8, 11) and once weekly during weeks 3 and 4 (days 15, 22). Patients continued their stable NA therapy throughout the study until end of study (day 211).",
            "interventionNames": [
              "DRUG: Placebo",
              "DRUG: Nucleos(t)ide analog (tenofovir disoproxil fumarate or entecavir)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.9,
          0.94,
          0.35,
          0.2
        ],
        [
          0.1,
          0.1,
          0.96,
          0.3
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "IONIS-HBVRx",
            "description": "Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection",
            "armGroupLabels": [
              "IONIS-HBVRx"
            ],
            "otherNames": [
              "ISIS 505358"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Bepirovirsen 300 mg",
            "description": "Bepirovirsen (ISIS 505358; GSK3228836) is an antisense oligonucleotide targeting all hepatitis B virus (HBV) messenger RNAs. Administered as 300 mg subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8, 11) and once weekly during weeks 3 and 4 (days 15, 22).",
            "armGroupLabels": [
              "Treatment-naïve: Bepirovirsen 300 mg",
              "On-NA: Bepirovirsen 300 mg"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Placebo",
            "armGroupLabels": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Placebo administered via subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8, 11) and once weekly during weeks 3 and 4 (days 15, 22).",
            "armGroupLabels": [
              "Treatment-naïve: Placebo",
              "On-NA: Placebo"
            ]
          }
        }
      ]
    }
  ]
}